News

Fluconazole was linked to improved Mayo and Harvey-Bradshaw scores; Iliev outlines the placebo-controlled trial needed next.

Raj Chovatiya, MD, PhD, discusses how the oral TYK2 inhibitor zasocitinib may affect scalp, nail, and hand psoriasis, clearance speed, and once-daily dosing.

Joseph Selvanayagam, MBBS, discusses the potential of implantable cardioverter-defibrillators to reduce sudden cardiac death among younger patients.

Weill Cornell investigator Iliyan D. Iliev, PhD, explains why fluconazole, not nystatin, cleared gut Candida in IBD.

Josh Woolley, MD, PhD, says active placebos fail to mask high-dose psilocybin and propose combining drug classes with authorized incomplete disclosure.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.

Raj Chovatiya, MD, PhD, explains where oral TYK2 inhibitor zasocitinib may fit in psoriasis treatment after the FDA accepted its NDA under priority review.

The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.

What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.

Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.

Astrid Paul Nordin, MD, PhD, discusses the results of the IDEAL-AF trial, highlighting the efficacy of including LVZ on top of PVI.

George Vasquez-Rios, MD, explains the barriers in GN care that ASN's new compendium may address.

A new ASN compendium curates scattered GN care guidance into one living resource, says nephrologist George Vasquez-Rios, MD

Anjali Owens, MD, discusses the long-term extension of the EXPLORER-HCM trial, demonstrating mavacamten’s safety and efficacy up to 5 years after initiation.

In his paper, Josh D. Woolley, MD, PhD, proposes multidrug active placebos and limited disclosure to finally mask high-dose psilocybin trials.

Where does Ameluz PDT fit next to Mohs surgery for skin cancer? Neal Bhatia, MD, on candidacy, adoption, and open questions.

The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.

In EMPA-KIDNEY, empagliflozin cut urinary uromodulin 63% without signs of tubular injury, reshaping views on SGLT2 inhibitor mechanisms.

The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.

What does FDA approval of Ameluz PDT for superficial BCC mean for dermatology? Neal Bhatia, MD, weighs in on the first-of-its-kind decision.

Sten Rubertsson, MD, PhD, discusses the results of the DISCO study, which compared immediate to deferred angiography in patients without ST-elevation following cardiac arrest.

George, of Royal Brompton Hospital discusses a phase 2a post hoc analysis showing increases in lung volume and reduced ILD.

Brendon Neuen explains why finerenone's mechanism supports combining it with immunosuppressive therapy in glomerulonephritis.

John Ostrominski, MD, discusses his analysis of the FINEARTS-HF trial, which showed finerenone’s improvements despite CKD, ASCVD, and/or metabolic disease.

In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.

In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.

New ASH guidelines recommend higher ferritin thresholds to improve the diagnosis of iron deficiency across key populations.

In this Q&A, Alysse Wurcel, MD, translates qualitative barriers into 8 concrete tactics healthcare practices can use to expand penicillin allergy delabeling.